These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia. Qanash H; Li Y; Smith RH; Linask K; Young-Baird S; Hakami W; Keyvanfar K; Choy JS; Zou J; Larochelle A Cells; 2021 Mar; 10(4):. PubMed ID: 33810313 [TBL] [Abstract][Full Text] [Related]
8. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028 [TBL] [Abstract][Full Text] [Related]
9. Eltrombopag: a review of its use in patients with severe aplastic anaemia. McCormack PL Drugs; 2015 Apr; 75(5):525-31. PubMed ID: 25700916 [TBL] [Abstract][Full Text] [Related]
10. Eltrombopag restores erythropoiesis in refractory adult acquired pure red cell aplasia. Liu X; Cheng L; He Y; Zhang R; Lu R; Zhang J; Hong M; He G; Li J Int J Hematol; 2021 Jul; 114(1):124-128. PubMed ID: 33611753 [TBL] [Abstract][Full Text] [Related]
11. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296 [TBL] [Abstract][Full Text] [Related]
12. Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation. Fattizzo B; Levati G; Cassin R; Barcellini W Drugs; 2019 Aug; 79(12):1305-1319. PubMed ID: 31292909 [TBL] [Abstract][Full Text] [Related]
13. Glucocorticoids improve erythroid progenitor maintenance and dampen Trp53 response in a mouse model of Diamond-Blackfan anaemia. Sjögren SE; Siva K; Soneji S; George AJ; Winkler M; Jaako P; Wlodarski M; Karlsson S; Hannan RD; Flygare J Br J Haematol; 2015 Nov; 171(4):517-29. PubMed ID: 26305041 [TBL] [Abstract][Full Text] [Related]
14. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. Svensson T; Chowdhury O; Garelius H; Lorenz F; Saft L; Jacobsen SE; Hellström-Lindberg E; Cherif H Eur J Haematol; 2014 Nov; 93(5):439-45. PubMed ID: 24853277 [TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia. Wu K; Thapar M; Farrell C; Hayes S; Guo H; Hou M; Zhang J Clin Ther; 2015 Jul; 37(7):1382-95. PubMed ID: 25929594 [TBL] [Abstract][Full Text] [Related]
17. Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy. Yamazaki H; Ohta K; Iida H; Imada K; Obara N; Tokumine Y; Tomiyama Y; Usuki K; Imajo K; Miyamura K; Sasaki O; Fanghong Z; Hattori T; Tajima T; Matsuda A; Nakao S Int J Hematol; 2019 Aug; 110(2):187-196. PubMed ID: 31183813 [TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043 [TBL] [Abstract][Full Text] [Related]
19. Eltrombopag as second line treatment in patients with primary immune thrombocytopenia: A single center real life experience. Gardellini A; Guidotti F; Feltri M; Zancanella M; Maino E; Ambrosiani L; Turrini M Blood Cells Mol Dis; 2021 Dec; 92():102620. PubMed ID: 34715450 [TBL] [Abstract][Full Text] [Related]
20. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. González-López TJ; Pascual C; Álvarez-Román MT; Fernández-Fuertes F; Sánchez-González B; Caparrós I; Jarque I; Mingot-Castellano ME; Hernández-Rivas JA; Martín-Salces M; Solán L; Beneit P; Jiménez R; Bernat S; Andrade MM; Cortés M; Cortti MJ; Pérez-Crespo S; Gómez-Núñez M; Olivera PE; Pérez-Rus G; Martínez-Robles V; Alonso R; Fernández-Rodríguez A; Arratibel MC; Perera M; Fernández-Miñano C; Fuertes-Palacio MA; Vázquez-Paganini JA; Gutierrez-Jomarrón I; Valcarce I; de Cabo E; Sainz A; Fisac R; Aguilar C; Paz Martínez-Badas M; Peñarrubia MJ; Calbacho M; de Cos C; González-Silva M; Coria E; Alonso A; Casaus A; Luaña A; Galán P; Fernández-Canal C; Garcia-Frade J; González-Porras JR Am J Hematol; 2015 Mar; 90(3):E40-3. PubMed ID: 25400215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]